Semagacestat (LY450139)

Catalog No.S1594

For research use only.

Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3.

Semagacestat (LY450139) Chemical Structure

CAS No. 425386-60-3

Selleck's Semagacestat (LY450139) has been cited by 18 publications

Purity & Quality Control

Choose Selective Gamma-secretase Inhibitors

Other Gamma-secretase Products

Biological Activity

Description Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3.
Features The best characterized γ-secretase inhibitor that has reached the clinic.
Targets
γ secretase(Aβ42) [1]
(H4 human glioma cells)
γ secretase(Aβ38) [1]
(H4 human glioma cells)
γ secretase(Aβ40) [1]
(H4 human glioma cells)
Notch [1]
(H4 human glioma cells)
10.9 nM 12.0 nM 12.1 nM 14.1 nM
In vitro

Semagacestat reduces the secretion of Aβ42, Aβ40 and Aβ38 from H4 human glioma cells stably overexpressing human wild-type APP into the culture medium, with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, respectively, without affecting cell viability. Semagacestat also increases β-CTF in cell lysates with ECmax of 16.0 nM, and the increase can be unexpectedly attenuated at high concentrations. Semagacestat inhibits Notch signaling with IC50 of 14.1 nM, and shows minimal Notch-sparing selectivity with Notch IC50/Aβ42 IC50 only 1.3. [1] Semagacestat causes a concentration-dependent decrease in Aβ40 secreted into the medium with IC50 of 111 nM from murine CTX expressing endogenous murine APP, but murine Aβ42 formation in CTX is roughly 12-fold less than Aβ40 in accordance with data for neurons from wild type mice. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO cells MYfGeY5kfGmxbjDhd5NigQ>? M1KxZWlvcGmkaYTpc44hd2ZiZ3HtcYEue2WlcnX0ZZNmKGmwIFPIU{Bk\WyuczDhd5Nme3OnZDDlfJBz\XO|aX7nJGFRWFO5IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYX35cI9q\CCkZYThLFEhfG9ieDmgd4VkemW2aX;uJIFnfGW{IH;2[ZJvcWeqdDDpcoN2[mG2aX;uJIJ6KEWOSWPBMEBGTDVyPUCuNFE2KM7:TR?= NFTp[IszOzdzM{[1Oi=>
human SH-SY5Y cells M3XG[WZ2dmO2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGejbX3hJJNm[3KndHHz[U1u\WSrYYTl[EBidXmub3nkJIJmfGFiKEGgeI8hPDBrIIDyc4R2[3Srb36gbY4hcHWvYX6gV2guW1l3WTDj[YxteyxiSVO1NF0xNjB|ODFOwG0> MYexPVY6PDR4Nx?=
African green monkey CV1 cells NX;BNXJDTnWwY4Tpc44h[XO|YYm= M1TjU2lvcGmkaYTpc44hd2ZiZ3HtcYEue2WlcnX0ZZNmKGW6cILld5Nm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[2:neIDy[ZN{cW6pIFfhcFQhTE6DLXLpcoRqdmdxdILhcpNi[3SrdnH0bY9vKGSxbXHpckBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJI5wfGOqIIDyc4Nme3OrbnegZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCjc4PhfUwhUUN3ME2wMlMyPjJ|IN88US=> MV:yNFA2PjV2MR?=
In vivo Oral administration of Semagacestat (1 mg/kg) to 5.5-month old APP-transgenic Tg2576 mice significantly ameliorates memory deficits on spatial working memory using the Y-maze task, which disappears after 8 days subchronic dosing. LY450139 decreases hippocampal levels of both Aβ42 and Aβ40 at 10 mg/kg (22-23% reduction) and 30 mg/kg (36-41% reduction) and increases β-CTF at 0.3-10 mg/kg in a dose dependent manner with no inhibition on the processing of other γ-secretase substrates, such as Notch, N-cadherin or EphA4, in the brain, but impairs normal cognition in wild-type mice and 3-month-old Tg2576 mice failing to restore cognitive deficits in the Y-maze test. [1]

Protocol (from reference)

Kinase Assay:[1]
  • Cellular APP processing assay and Notch signaling assay:

    H4 human glioma cells stably overexpressing human wild-type APP695 are treated with Semagacestat at various concentrations for 24 hours. Levels of Aβ42, Aβ40, and Aβ38 in the media are measured using separate ELISA kits. The expression vector of the constitutively active form of Notch (NotchΔE), encoding bases 1-60 and 5193-6657 of the human Notch1 coding region (NM_017617), is constructed into a pcDNA3.1 vector with a sequence modification from mouse to human. Notch signaling activity is evaluated using Cignal RBP-Jk Reporter Assay kit. RBP-Jk protein [CSL/CBF1/Su(H)/Lag1] is a transcription factor activated with Notch intracellular domain produced by γ-secretase. H4 cells are transiently transfected with the human NotchΔE expression vector and the RBP-Jk-responsive luciferase construct using Lipofectamine 2000, and then exposed to various concentrations of Semagacestat for 16 hours. Notch signaling is measured based on luciferase activity in the cell lysate using the Dual-Glo Luciferase Assay System.

Cell Research:[2]
  • Cell lines: Murine cortical neurons and cerebellar granule cells
  • Concentrations: Dissolved in DMSO, final concentration ~10 μM
  • Incubation Time: 24 hours
  • Method: Cells are incubated with Semagacestat for 24 hours. For detection of cell viability, the percentage of viable cells is quantified by their capacity to reduce 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) following incubation with 0.5 mg/mL MTT for 60 minutes. For the detection of sAPP species, cells are lysed and analysed by western blotting.
Animal Research:[1]
  • Animal Models: Female Tg2576 mice expressing human APP695 with the Swedish mutation (K670N/M671L)
  • Dosages: ~30 mg/kg
  • Administration: Orally administered once daily

Solubility (25°C)

In vitro

DMSO 72 mg/mL
(199.2 mM)
Ethanol 41 mg/mL
(113.43 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% methylcellulose
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 361.44
Formula

C19H27N3O4

CAS No. 425386-60-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C(C(=O)NC(C)C(=O)NC1C2=CC=CC=C2CCN(C1=O)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01035138 Completed Drug: semagacestat Alzheimer''s Disease Eli Lilly and Company December 2009 Phase 3
NCT00762411 Completed Drug: LY450139|Drug: Placebo Alzheimer''s Disease Eli Lilly and Company September 2008 Phase 3
NCT00594568 Completed Drug: LY450139|Drug: Placebo Alzheimer''s Disease Eli Lilly and Company March 2008 Phase 3
NCT00765115 Completed Drug: LY450139|Drug: placebo Alzheimer Disease Eli Lilly and Company July 2006 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Semagacestat (LY450139) | Semagacestat (LY450139) supplier | purchase Semagacestat (LY450139) | Semagacestat (LY450139) cost | Semagacestat (LY450139) manufacturer | order Semagacestat (LY450139) | Semagacestat (LY450139) distributor